Abstract
Osimertinib is a third-generation, irreversible EGFR-tyrosine kinase inhibitor (TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR-T790M-resistant mutations. In a phase III trial (FLAURA), osimertinib showed efficacy superior to that of first-generation gefitinib and erlotinib, with a similar safety profile and lower rates of serious adverse events. Osimertinib is currently being used as the first-line treatment for patients with advanced EGFR mutation-positive NSCLC. However, the efficacy and safety of osimertinib treatment in clinical practice have not been fully verified.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
